Silexion Therapeutics Corp SLXN
We are a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog ("KRAS"). The KRAS gene, when mutated, plays a central role in many cancer types, such as pancreatic, colorectal and lung, and is therefore considered to be an oncogene. This oncogene instructs cells to make the corresponding KRAS protein which has a controlling function in cell growth signaling in the cancer cells. While multiple pharmaceutical companies are pursuing strategies to inhibit or tag the KRAS protein for degradation and thereby limit its downstream signaling, our approach is differentiated by targeting the root cause of oncogenic signaling— we silence the KRAS oncogene itself, preventing the production of the oncogenic protein.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $155.0K | $28.0K | $153.0K | — |
| R&D | $7.1M | $5.8M | $3.7M | — |
| SG&A | $4.5M | $6.8M | $973.0K | — |
| Total operating expenses | $11.6M | $12.6M | $4.7M | — |
| Operating income | -$11.6M | -$12.6M | -$4.7M | — |
| Pre-tax income | -$11.9M | -$16.5M | -$5.1M | — |
| Income tax | $3.0K | $10.0K | $32.0K | — |
| Net income | -$11.9M | -$16.5M | -$5.1M | — |
| EPS, basic | 89.61 | 3,955.11 | 659.55 | — |
| EPS, diluted | 89.61 | 3,955.11 | 659.55 | — |
| Shares, diluted (wtd. avg.) | 132,951 | 4,157 | 7,493 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $6.0M | $1.2M | $4.6M | $8.3M |
| Total current assets | $6.6M | $2.2M | $5.0M | — |
| Property, plant and equipment | $25.0K | $30.0K | $49.0K | — |
| Total assets | $7.2M | $2.9M | $5.3M | — |
| Accounts payable | $787.0K | $929.0K | $319.0K | — |
| Total current liabilities | $2.8M | $3.5M | $2.2M | — |
| Total liabilities | $4.6M | $6.9M | $2.3M | — |
| Retained earnings | -$55.2M | -$43.3M | -$26.8M | — |
| Total equity | $2.6M | -$4.0M | $3.0M | $7.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$8.4M | -$4.5M | — |
| Depreciation and amortisation | $14.0K | $25.0K | $45.0K | — |
| Stock-based compensation | $134.0K | $5.9M | $130.0K | — |
| Capital expenditure | $9.0K | $22.0K | $12.0K | — |
| Investing cash flow | -$14.0K | -$22.0K | $573.0K | — |
| Financing cash flow | $15.6M | $5.1M | $522.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001178913-26-004003.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $153.0K | $28.0K | $155.0K |
| Gross profit | — | — | — | — |
| Net income | — | -$5.1M | -$16.5M | -$11.9M |
Recent filings and events
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Item 7.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $237.48B | 30.9x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $193.48B | 23.0x | 2.4% |
| MRNA | Moderna, Inc. | $79.89B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $40.08B | — | — |
| BIIB | BIOGEN INC. | $37.01B | 28.5x | 2.2% |
| EXEL | EXELIXIS, INC. | $15.99B | 23.2x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.51B | 30.6x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.26B | 49.1x | 37.6% |